A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia

NCT ID: NCT07011953

Last Updated: 2025-06-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-01
• Study Completion Date: 2027-07-01

Brief Summary

The goal of this clinical trial is to investigate whether adjunctive thyroxine treatment can ameliorate motivation deficits in adults with schizophrenia experiencing predominant avolition (core negative symptom).

The main questions it aims to answer are:

• Does adjunctive thyroxine reduce avolition symptoms compared to placebo?
• Does adjunctive thyroxine normalize cortico-striatal circuit activity during reward processing?

Researchers will compare the treatment group (adjunctive sodium tablets, 50μg/day) with the control group (dose-equivalent placebo starch tablet) to see if thyroid hormone:

1. Significantly improves clinical scores of avolition

2. Modulates neural activation in motivation-processing brain circuits

Participants will:

• Maintain stable antipsychotic therapy for 8 weeks
• Receive daily levothyroxine/placebo tablets
• Complete the following assessments pre-/post-treatment:
• Clinical evaluations (PANSS, NSA, PSP)
• MRI scans (resting-state, structural, fMRI during reward tasks)
• Blood tests
• Behavioral motivation tasks

Conditions

Schizophrenia; Avolition

Study Design

• Allocation Method: NA
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Treatment group: adjunctive thyroxine

Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks. Manufacturer: Merck Serono Ltd.

Group Type: EXPERIMENTAL

Antipsychotics plus Levothyroxine Sodium

Intervention Type: DRUG

Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks. Manufacturer: Merck Serono Ltd. Levothyroxine Sodium Tablets should be administered as a single daily dose on an empty stomach, 30 minutes before breakfast, with sufficient liquid (e.g., half a glass of water).

Placebo Control group

The placebo control group will maintain the original antipsychotic regimen, supplemented with a dose-equivalent placebo tablet (starch tablet) matching levothyroxine sodium in appearance and nominal dosage (50 μg/day) for 8 weeks. Manufacturer: Boji Medical Technology Co., Ltd.

Group Type: PLACEBO_COMPARATOR

Antipsychotics plus Placebo

Intervention Type: DRUG

All participants maintain pre-study antipsychotic medication at stable doses. ADDITIONALLY, they receive a visually identical placebo tablet.

Placebo characteristics & Blinding guaranteet: Matches levothyroxine in appearance (size/color/coating), taste, and packaging.

Active ingredien : starch tablet with no biological activity. Administration: Once daily in the morning under identical fasting conditions.

Interventions

Antipsychotics plus Levothyroxine Sodium

Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks. Manufacturer: Merck Serono Ltd. Levothyroxine Sodium Tablets should be administered as a single daily dose on an empty stomach, 30 minutes before breakfast, with sufficient liquid (e.g., half a glass of water).

Intervention Type: DRUG

Antipsychotics plus Placebo

All participants maintain pre-study antipsychotic medication at stable doses. ADDITIONALLY, they receive a visually identical placebo tablet.

Placebo characteristics & Blinding guaranteet: Matches levothyroxine in appearance (size/color/coating), taste, and packaging.

Active ingredien : starch tablet with no biological activity. Administration: Once daily in the morning under identical fasting conditions.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Meet the diagnostic criteria for schizophrenia according to the International Classification of Diseases, 10th Revision (ICD-10) (World Health Organization, 1993);

2. Aged between 18 and 45 years, right-handed;

3. Currently clinically stable, with the primary antipsychotic medication formulation and dosage unchanged for at least 4 weeks, and a total PANSS score ≤ 60;

4. Predominant avolition symptoms, defined as a score ≥ 16 on the Motivation subscale of the Negative Symptom Assessment (NSA-15) (Zhou et al., 2023), with fewer than 3 items scoring ≥ 4 and fewer than 2 items scoring ≥ 5 on the PANSS positive subscale (Rabinowitz et al., 2013);

5. Receiving one or two second-generation antipsychotics (SGAs), with stable medication doses for at least 1 month;

6. Willingness and ability to maintain stable medication doses throughout the trial period;

7. Capacity to understand study procedures, cooperate with all testing requirements, and provide written informed consent.

Exclusion Criteria

1. Current treatment with clozapine or first-generation antipsychotics;

2. Current use of thyroid hormone medications or presence of thyroid dysfunction;

3. Hypersensitivity to levothyroxine sodium; or history of non-hypothyroid-related heart failure, tachyarrhythmias, or recent myocardial infarction;

4. Current use of medications known to interact with levothyroxine sodium that may affect its efficacy or safety (e.g., antidiabetic drugs, coumarin derivatives);

5. History of endocrinological or cardiovascular/cerebrovascular diseases;

6. IQ < 80 assessed by the Chinese short-form Wechsler Adult Intelligence Scale (Gong, 1981);

7. History of substance abuse or drug addiction;

8. History of traumatic brain injury or neurological disorders;

9. Receiving electroconvulsive therapy (ECT) within the last 3 months;

10. Pregnancy, lactation, or planning pregnancy within the next 2 months (for female participants);

11. Claustrophobia; implanted metal devices (e.g., prosthetic implants, pacemakers); or other contraindications to MRI scanning.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University

OTHER

Sponsor Role: lead

Responsible Party

Xin Yu

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

2025-06-02

Identifier Type: -

Identifier Source: org_study_id